

CORRECTION

Open Access



Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Toshinari Yamashita^{1*}, Norikazu Masuda², Shigehira Saji³, Kazuhiro Araki⁴, Yoshinori Ito⁵, Toshimi Takano⁶, Masato Takahashi⁷, Junji Tsurutani⁸, Kei Koizumi⁹, Masahiro Kitada¹⁰, Yasuyuki Kojima¹¹, Yasuaki Sagara¹², Hiroshi Tada¹³, Tsutomu Iwasa¹⁴, Takayuki Kadoya¹⁵, Tsuguo Iwatani¹⁶, Hiroki Hasegawa¹⁷, Satoshi Morita¹⁸ and Shinji Ohno¹⁹

Correction to: *Trials* (2020) 21:391

<https://doi.org/10.1186/s13063-020-04341-y>

Following publication of the original article [1], the authors identified an error in Fig. 1, due to the change of the study protocol version (from 1.1 to 2.0). The following points in Fig. 1 need to be changed:

- The end of the registration period will be extended from April 2020 to December 2020.
- The duration of registration period will be changed from 33 to 41 months.
- The end of the follow-up period will be extended from April 2022 to December 2022.

- The end of the survival survey will be extended from October 2023 to June 2024.

The same changes apply to the text as well, as follows:

Trial Status section

- This study opened for recruitment in August 2017, with recruitment expected to be completed by December 2020. The first patient was enrolled in October 2017, and the actual number of patients recruited as of January 31, 2020 was 244.
- The current protocol is version 2.0 and was approved on November 5, 2019. Because of delayed registration, the registration and follow-up period for OS will be until December 2020 and June 2024, respectively.

Follow-up section

- All participants will be followed up until December 2022, i.e., 2 years after the last participant recruitment.

The correct Fig. 1 is presented below:

The original article can be found online at <https://doi.org/10.1186/s13063-020-04341-y>.


* Correspondence: tyamashita@kcch.jp

¹Department of Breast Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama-shi, Kanagawa 241-8515, Japan

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



Author details

¹Department of Breast Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama-shi, Kanagawa 241-8515, Japan. ²Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Chuou-ku, Osaka 540-0006, Japan. ³Department of Medical Oncology, Fukeushima Medical University, 1 Hikarigaoka Fukushima, Fukushima 960-1295, Japan. ⁴Department of Breast Surgery, Gunma Prefectural Cancer Center, 617-1 Takahayashinishicho, Ota, Gunma 373-8550, Japan. ⁵Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of JFCR, 3-8-31 Ariake Koto-ku, Tokyo 135-8550, Japan. ⁶Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan. ⁷Breast Surgery, NHO Hokkaido Cancer Center, 2-3-54 Yonjyo Kikusui Shiraishi-ku, Sapporo-shi, Hokkaido 003-0804, Japan. ⁸Department of Medical Oncology, Showa University Hospital, 1-5-8 Hatanodai Shinagawa-ku, Tokyo 142-8666, Japan. ⁹First Department of Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu City, Shizuoka 431-3192, Japan. ¹⁰Breast Disease Center, Asahikawa Medical University Hospital, 1-1 Higashi 2-jo 1-chome, Midorigaoka, Asahikawa-shi, Hokkaido 078-8510, Japan. ¹¹Department of Breast Surgery, St. Marianna University School of Medicine Hospital, 2-16-1 Sugao Miyamae-ku, Kawasaki-shi, Kanagawa 216-8511, Japan. ¹²Breast Surgical Oncology, Sagara Hospital, 3-31 Matsubaracho Kagoshima-shi, Kagoshima 892-0833, Japan. ¹³Department of Breast and Endocrine Surgical Oncology, Tohoku University Hospital, 1-1 Seiryochi Aoba-ku, Sendai-shi, Miyagi 980-8574, Japan. ¹⁴Oncology Internal Medicine, Kindai University Hospital, 377-2 Ohnohigashi Sayama-shi Osaka, Osaka 589-8511, Japan. ¹⁵Breast Surgery, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8551, Japan. ¹⁶Department of Breast Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. ¹⁷Eisai Co., Ltd., 4-6-10 Koishikawa Bunkyo-ku, Tokyo 112-8088, Japan. ¹⁸Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine Kyoto University, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. ¹⁹Breast Oncology Center, The Cancer Institute Hospital of JFCR, 3-8-31 Ariake Koto-ku, Tokyo 135-8550, Japan.

Published online: 08 June 2020

Reference

1. Yamashita T, et al. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). *Trials*. 2020;21:391. <https://doi.org/10.1186/s13063-020-04341-y>.